Discover
LSTA
Lisata Therapeutics, Inc.
3.36
3 x 3.36
1 x 3.39
bid
ask
-
0.04
1.18%
2 @ 04:00 PM
3.36 +0.00 (0.00%)
| Ytd | 80.65% | |
| 1y | 17.48% |
3.36
day range
3.40
1.81
52 week range
5.07
| Open | 3.37 | Prev Close | 3.40 | Low | 3.36 | High | 3.40 | Mkt Cap | 30.60M |
| Vol | 74.41K | Avg Vol | 114.14K | EPS | -1.86 | P/E | N/A | Forward P/E | -1.20 |
| Beta | 1.22 | Short Ratio | 1.79 | Inst. Own | 9.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.32 | 200-d Avg | 3.23 | 1yr Est | 14.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.75 | -0.59 | 0.16 | 21.33% |
| 2024-08-12 | 2024-06 | -0.75 | -0.61 | 0.14 | 18.67% |
| 2024-05-09 | 2024-03 | -0.73 | -0.65 | 0.08 | 10.96% |
| 2024-02-29 | 2023-12 | -0.86 | -0.66 | 0.2 | 23.26% |
| 2023-11-02 | 2023-09 | -0.93 | -0.65 | 0.28 | 30.11% |
| 2023-08-14 | 2023-06 | -0.7 | -0.5 | 0.2 | 28.57% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-08 | AZAB MOHAMMAD | Director | 58.68K | Stock Award(Grant) |
| 2024-01-08 | BROWN GREGORY B | Director | 49.41K | Stock Award(Grant) |
| 2024-09-30 | BUCK KRISTEN K | Officer | 62.67K | Stock Award(Grant) |
| 2024-01-08 | FLOWERS CYNTHIA LOUISE | Director | 49.20K | Stock Award(Grant) |
| 2024-01-08 | HENSON HEIDI | Director | 39.48K | Stock Award(Grant) |
| 2024-01-08 | KLOSK STEVEN MARK | Director | 49.57K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | BML Capital Management, LLC | 284.67K | 859.70K | 3.39% |
| 2024-09-29 | Vanguard Group Inc | 186.37K | 562.83K | 2.22% |
| 2024-09-29 | Renaissance Technologies, LLC | 103.62K | 312.94K | 1.23% |
| 2024-09-29 | Blackrock Inc. | 56.01K | 169.16K | 0.67% |
| 2024-09-29 | Geode Capital Management, LLC | 55.68K | 168.16K | 0.66% |
| 2024-09-29 | Dimensional Fund Advisors LP | 17.34K | 52.37K | 0.21% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 127.74K | 385.77K | 1.52% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 57.60K | 173.94K | 0.69% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 39.41K | 119.00K | 0.47% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 5.46K | 16.49K | 0.07% |
| 2024-07-30 | Dimensional ETF Tr-Dimensional U.S. Equity ETF | 3.85K | 11.63K | 0.05% |
| 2024-10-30 | Fidelity Total Market Index Fund | 4.38K | 13.22K | 0.05% |
Dividend
| Dividend | Date |
|---|---|
| 0.0021 | 2013-10-28 |
| 0.0002 | 2011-04-04 |
Split
| Split | Date |
|---|---|
| 1 : 15 | 2022-09-15 |
| 1 : 10 | 2016-07-28 |
| 1 : 10 | 2013-07-16 |
| 1 : 10 | 2007-08-09 |
| 1 : 10 | 2006-08-31 |